Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Average PT from Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been assigned a consensus rating of "Buy" from the nine analysts that are currently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $7.43.

TRVI has been the subject of a number of research analyst reports. Leerink Partnrs raised shares of Trevi Therapeutics to a "strong-buy" rating in a research report on Monday, September 9th. B. Riley reaffirmed a "buy" rating and set a $6.00 price objective on shares of Trevi Therapeutics in a research report on Monday, October 7th. Leerink Partners assumed coverage on shares of Trevi Therapeutics in a research report on Monday, September 9th. They set an "outperform" rating and a $7.00 price objective for the company. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a "strong-buy" rating in a research report on Monday, August 19th. Finally, Raymond James assumed coverage on shares of Trevi Therapeutics in a research report on Friday, August 30th. They set an "outperform" rating and a $9.00 price objective for the company.

Trevi Therapeutics Stock Performance

Shares of NASDAQ TRVI traded down $0.14 during trading on Wednesday, hitting $2.86. The company had a trading volume of 288,182 shares, compared to its average volume of 291,716. The company has a market cap of $219.85 million, a P/E ratio of -6.55 and a beta of 1.01. Trevi Therapeutics has a 52 week low of $0.97 and a 52 week high of $4.00. The business's 50-day moving average is $3.15 and its 200 day moving average is $2.92.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same period in the previous year, the firm posted ($0.08) EPS. On average, research analysts expect that Trevi Therapeutics will post -0.49 EPS for the current year.

Insider Transactions at Trevi Therapeutics

In other Trevi Therapeutics news, insider Thomas Sciascia sold 18,660 shares of the firm's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $2.76, for a total value of $51,501.60. Following the completion of the sale, the insider now directly owns 220,315 shares in the company, valued at approximately $608,069.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Thomas Sciascia sold 18,660 shares of Trevi Therapeutics stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the transaction, the insider now directly owns 220,315 shares in the company, valued at $608,069.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jennifer L. Good sold 10,981 shares of Trevi Therapeutics stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the transaction, the chief executive officer now owns 213,313 shares of the company's stock, valued at $644,205.26. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,255 shares of company stock worth $116,388 over the last three months. 24.37% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets raised its position in Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company's stock worth $40,000 after acquiring an additional 6,764 shares during the period. American Century Companies Inc. increased its stake in shares of Trevi Therapeutics by 17.1% in the second quarter. American Century Companies Inc. now owns 54,108 shares of the company's stock worth $161,000 after purchasing an additional 7,902 shares in the last quarter. MAI Capital Management increased its stake in shares of Trevi Therapeutics by 0.7% in the third quarter. MAI Capital Management now owns 1,327,285 shares of the company's stock worth $4,433,000 after purchasing an additional 8,789 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Trevi Therapeutics by 87.6% in the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company's stock worth $73,000 after purchasing an additional 11,450 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD purchased a new position in shares of Trevi Therapeutics in the first quarter worth about $47,000. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.